Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways-Reference-Cited by-同舟云学术

Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways

Published:2024-04 Issue:4 Volume:300 Page:105784
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Sonnentag Sophia J.,Dopler Arthur,Kleiner Katharina,Garg Brijesh K.,Mannes Marco,Späth Nadja,Akilah Amira,Höchsmann Britta,Schrezenmeier Hubert,Anliker Markus,Boyanapalli Ruby,Huber-Lang Markus,Schmidt Christoph Q.

Funder

Takeda Pharmaceuticals USA Inc

Takeda Pharmaceutical Company

DFG

Publisher

Elsevier BV

Reference55 articles.

1. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria;Hillmen;N. Engl. J. Med.,2006

2. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome;Legendre;N. Engl. J. Med.,2013

3. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study;Howard;Lancet Neurol.,2017

4. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder;Pittock;N. Engl. J. Med.,2019

5. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study;Lee;Blood,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement‐targeted therapeutics: Are we there yet, or just getting started?;European Journal of Immunology;2024-09-12

2. The complement model disease paroxysmal nocturnal hemoglobinuria;European Journal of Immunology;2024-08-05